Top news of the week: 17.03.2020.
#coronavirus #COVID19 #SeriesC #targetedproteindegradation #biotech
Startups
Two excellent pieces from two of biotwitter's own luminaries
Five Easy Steps to Take during the #COVID19 Pandemic
by @DanChenMDPhD
https://t.co/rd77ac4ecs
Lessons from Italy: How the US can respond to the urgent #coronavirus threat
by @OtelloVC
https://t.co/BdiTLmVTlq
OpenLessons from Italy: How the US Can Respond to the Urgent Coronavirus Threat
As background: I am Italian-born, and was raised in Italy. My entire family works and lives there, mostly in Milan or nearby areas. I have been communicating with family members about the ...
Great news this morning from @KymeraTx: the LabCentral alumni closed a $102 Million Series C financing round to advance its protein degrader pipeline and platform. More here: https://t.co/8HPQSFzl4w
OpenKymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform
Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a ...
We should prioritize novel coronavirus treatments first, experts say. See why and other projections: https://t.co/JYcv2llrl6 https://t.co/DC86yK66ZA
OpenLook for novel coronavirus treatments first, experts say, and vaccines are farther off than you think
What's the outlook for really fending off the novel coronavirus? Small molecule drugs and other therapeutics will obviously beat vaccines to market, and Gilead's remdesivir, if effective, ...
RT @adamfeuerstein: $125M effort to find #coronavirus drugs started by Gates Foundation, Wellcome, and Mastercard https://t.co/doD3ZRaDGt via @matthewherper
Open$125M effort to find coronavirus drugs started by Gates Foundation, Wellcome, and Mastercard
The Gates Foundation, Wellcome, and Mastercard are funding the initiative, which will start by testing existing antiviral drugs against Covid-19.
How the Biogen leadership conference in Boston spread the coronavirus
Amid ominous signs after a routine conference, a frightening realization slowly dawned: The virus was on the loose.
Harbour BioMed reels in $75M as proprietary pipeline hits clinic https://t.co/L3yuDWdDf3 https://t.co/VhR0H5XxvV
OpenHarbour BioMed reels in $75M as proprietary pipeline hits clinic
Harbour BioMed has raised $75 million to continue moving multiple candidates through the clinic. The round, which Harbour described as a “series B+,” comes shortly after the antibody ...
As it stands, Genscript Biotech owns the lion’s share of Legend. However, with JNJ-4528 closing in on a filing for approval and Legend trialing multiple other CAR-T therapies that are driving up Genscript’s costs https://t.co/K5JvYAAmKQ
OpenJ&J partner Legend plans IPO to fund CAR-T pipeline
Legend Biotech has filed for an IPO. The Chinese CAR-T player plans to list its stock in the U.S. to fund the advance of a pipeline spearheaded by Johnson & Johnson-partnered anti-BCMA ...
With weeks to go to COVID-19 vaccine trial, BioNTech lands $135M deal and advances Pfizer talks https://t.co/nx0spERCfi https://t.co/PDo03HkvMK
OpenWith weeks to go to COVID-19 vaccine trial, BioNTech lands $135M deal and advances Pfizer talks
BioNTech is in advanced talks with Pfizer over ex-China development of a coronavirus vaccine that is due to enter the clinic late next month. News of the progress of the vaccine and ...